AMS:AGN - AEGON Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: €0.00
  • Forecasted Upside: NaN
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
€0.00
+0.30 (1.20%)
1 month | 3 months | 12 months
Get New AEGON Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for AGN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for AGN

Average Price Target: €0.00
This price target is based on 0 analysts offering 12 month price targets for AEGON in the last 3 months. The average price target is €0.00, with a high forecast of €0.00 and a low forecast of €10,000,000.00. The average price target represents a NaN upside from the last price of €0.00.

N/A

The current consensus among 0 investment analysts is to n/a stock in AEGON. This rating has held steady since July 2019, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/29/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/28/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/26/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/24/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/23/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/23/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/22/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/21/2021

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
7/5/2018HSBCSet Price TargetBuy€6.50
(Data available from 6/21/2016 forward)
AEGON logo
Allergan plc, a pharmaceutical company, develops, manufactures, and commercializes branded pharmaceutical, device, biologic, surgical, and regenerative medicine products worldwide. The company operates in three segments: US Specialized Therapeutics, US General Medicine, and International. It offers a portfolio of products in various therapeutic areas, including medical aesthetics and dermatology, eye care, neuroscience, urology, gastrointestinal, women's health, and anti-infective therapeutic products. The company also offers breast implants and tissue expanders; and RM-131 (relamorelin), a peptide ghrelin agonist for the treatment of diabetic gastroparesis. In addition, it develops medical and cosmetic treatments; therapies for non-alcoholic steatohepatitis and other liver diseases; inhibitor for the treatment of psoriasis and other autoimmune disorders; atopic dermatitis drug candidate; peri-ocular rings for extended drug delivery and reducing elevated intraocular pressure in glaucoma patients; and treatments for neurodegenerative disorders, including Alzheimer's disease. Further, the company develops RST-001, a novel gene therapy for the treatment of retinitis pigmentosa; small molecule therapeutics for inflammatory and fibrotic diseases; topical medicines for fat reduction; and delivery system and botulinum toxin-based prescription products. It has collaboration, option, and license agreement with Lyndra, Inc.; and strategic alliance and option agreement with Editas Medicine, Inc. Allergan plc also has licensing agreements with Assembly Biosciences, Inc.; MedImmune; and Heptares Therapeutics, Ltd. The company was formerly known as Actavis plc and changed its name to Allergan plc in June 2015. Allergan plc was founded in 1983 and is headquartered in Dublin, Ireland.
Read More

Today's Range

Now: N/A

50 Day Range

MA: N/A

52 Week Range

Now: N/A

Volume

5,500,000 shs

Average Volume

9,270,000 shs

Market Capitalization

N/A

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of AEGON?

The following equities research analysts have issued research reports on AEGON in the last twelve months:
View the latest analyst ratings for AGN.

What is the current price target for AEGON?

0 Wall Street analysts have set twelve-month price targets for AEGON in the last year. has the lowest price target set, forecasting a price of €10,000,000.00 for AEGON in the next year.
View the latest price targets for AGN.

What is the current consensus analyst rating for AEGON?

AEGON currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for AGN.

What other companies compete with AEGON?

How do I contact AEGON's investor relations team?

AEGON's physical mailing address is AEGONplein 50, 'S-GRAVENHAGE, 2591 TV, Netherlands. The company's listed phone number is +31-70-3443210. The official website for AEGON is www.aegon.nl.